Drug Profile
Adsorbed diphtheria-purified pertussis-tetanus combined vaccine - BIKEN/Mitsubishi Tanabe Pharma
Alternative Names: BK 1301; DTaP vaccine - BIKEN/Mitsubishi Tanabe Pharma; TribikLatest Information Update: 22 Aug 2017
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation; Research Foundation for Microbial Diseases of Osaka University
- Developer BIKEN; Mitsubishi Tanabe Pharma Corporation
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Pertussis; Tetanus
Most Recent Events
- 30 Apr 2015 Mitsubishi Tanabe Pharma files sNDA for stage 2 vaccination in prophylaxis of patients with Diphtheria, Pertusis and Tetanus in Japan (Mitsubishi Tanabe Pharma pipeline, May 2015)
- 01 Aug 2014 Mitsubishi Tanabe Pharma completes a phase III trial in Diphtheria, Pertussis and Tetanus (Prevention, In adolescents) in Japan (NCT02118961)
- 30 Apr 2014 Mitsubishi Tanabe Pharma in collaboration with the Research Foundation for Microbial Diseases of Osaka University initiates phase-III clinical trials in Pertussis (Prevention, In adolescents) in Japan (SC) (NCT02118961)